Paul L Hess

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials
    Paul L Hess
    From the Duke Clinical Research Institute, Durham, NC P L H, S M A, R E, K L L, D B M, G S University of Washington, Seattle J Y H, G H B, A H, P J K, L Y T I Columbia University, New York, NY J T B, R S Beth Israel Deaconess Medical Center, Boston, MA A B I R C C S Policlinico San Donato, Milan, Italy R C University of Toronto, Ontario, Canada P D Northwestern Feinberg School of Medicine, Chicago, IL A H K and University of Rochester, Rochester, NY A J M
    Circ Cardiovasc Qual Outcomes 8:179-86. 2015
  2. pmc Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am Heart J 168:239-247.e1. 2014
  3. pmc Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease
    Paul L Hess
    From the Duke Clinical Research Institute, Durham, NC P L H, A S H, E D P, G d S, H R A K, L H C, B G H, P H P, K J A, S M A K Department of Medicine, Duke University Medical Center, Durham, NC P L H, A S H, E D P, P H P, S M A K Department of Medicine, Yale University, New Haven, CT J P C and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN S C H
    Circ Arrhythm Electrophysiol 7:793-9. 2014
  4. pmc Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:1127-33. 2013
  5. pmc Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    J Cardiovasc Electrophysiol 24:664-71. 2013
  6. pmc Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 126:625-32.e1. 2013
  7. pmc Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:828-35. 2013
  8. pmc Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    Curr Cardiol Rep 15:330. 2013
  9. pmc Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Clin Cardiol 35:649-57. 2012
  10. doi request reprint Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials
    Patrick H Pun
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am J Kidney Dis 64:32-9. 2014

Detail Information

Publications12

  1. doi request reprint Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials
    Paul L Hess
    From the Duke Clinical Research Institute, Durham, NC P L H, S M A, R E, K L L, D B M, G S University of Washington, Seattle J Y H, G H B, A H, P J K, L Y T I Columbia University, New York, NY J T B, R S Beth Israel Deaconess Medical Center, Boston, MA A B I R C C S Policlinico San Donato, Milan, Italy R C University of Toronto, Ontario, Canada P D Northwestern Feinberg School of Medicine, Chicago, IL A H K and University of Rochester, Rochester, NY A J M
    Circ Cardiovasc Qual Outcomes 8:179-86. 2015
    ..The impact of patient age on the risks of death or rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain...
  2. pmc Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am Heart J 168:239-247.e1. 2014
    ....
  3. pmc Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease
    Paul L Hess
    From the Duke Clinical Research Institute, Durham, NC P L H, A S H, E D P, G d S, H R A K, L H C, B G H, P H P, K J A, S M A K Department of Medicine, Duke University Medical Center, Durham, NC P L H, A S H, E D P, P H P, S M A K Department of Medicine, Yale University, New Haven, CT J P C and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN S C H
    Circ Arrhythm Electrophysiol 7:793-9. 2014
    ..Guidelines recommend that implantable cardioverter-defibrillator (ICD) candidates have an estimated longevity of ≥1 year. Longevity can be affected by chronic kidney disease (CKD)...
  4. pmc Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:1127-33. 2013
    ..A 2008 expert consensus statement recommended an in-person follow-up visit between 2 and 12 weeks after the placement of a new cardiovascular implantable electronic device (CIED)...
  5. pmc Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    J Cardiovasc Electrophysiol 24:664-71. 2013
    ..Practice guidelines recommend the use of ICDs in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≤ 35% in the absence of contraindications...
  6. pmc Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 126:625-32.e1. 2013
    ..Patients with atrial fibrillation often have cardiovascular risk factors or known comorbid disease, yet the use of evidence-based primary and secondary prevention cardiac therapy among atrial fibrillation outpatients is unknown...
  7. pmc Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:828-35. 2013
    ..Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown...
  8. pmc Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    Curr Cardiol Rep 15:330. 2013
    ..107 (95 % confidence interval 0.069-0.163). Prospective studies, particularly among patients not meeting traditional CRT criteria, are needed...
  9. pmc Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Clin Cardiol 35:649-57. 2012
    ..Warfarin use and associated outcomes in patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device have not been described previously...
  10. doi request reprint Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials
    Patrick H Pun
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am J Kidney Dis 64:32-9. 2014
    ..The benefit of a primary prevention implantable cardioverter-defibrillator (ICD) among patients with chronic kidney disease is uncertain...
  11. pmc Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice?
    Sana M Al-Khatib
    Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Arrhythm Electrophysiol 6:108-16. 2013
    ..A 2008 expert consensus statement outlined the minimum frequency of follow-up of patients with cardiovascular implantable electronic devices (CIEDs)...
  12. doi request reprint Catheter Ablation for Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator (CALYPSO) Pilot Trial
    Sana M Al-Khatib
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
    J Cardiovasc Electrophysiol 26:151-7. 2015
    ....